Midatech and Monosol Rx Announce Filing of Joint Patent Application for Nanoparticle Film Delivery Systems
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Midatech Group Ltd., and MonoSol Rx have announced the filing of a provisional US patent application for “Nanoparticle Film Delivery Systems.” The applications submitted to the United States Patent and Trademark Office (USPTO) relate to therapeutic uses of nanoparticle-based proteins and peptides delivered in pharmaceutical films.
The Nanoparticle film delivery system could be used to overcome the difficulties associated with the delivery of biologic therapies to the circulatory system, allowing for an efficient delivery system of biologics, through buccal or sublingual administration.
The delivery system facilitates transport of a therapy into the bloodstream without exposure to the gastrointestinal tract of the patient, avoiding gastrointestinal destruction and/or side-effects often associated with the oral drug delivery of certain molecules. Additionally, the combination of these technologies allows for the oral delivery of an entire class of therapies previously available primarily through injection.
The joint patent application relates to film delivery systems comprising nanoparticles, particularly for use in medicine, and includes methods and systems for the treatment of disorders of blood glucose in diabetic conditions. The patent is directed at compositions, delivery systems, products and methods of making and administering such compositions to sufferers.
Commenting on the filing of the patent, Professor Tom Rademacher, Chairman of Midatech Group said: “The filing of this patent will enable us to fully commercialize this exciting new drug delivery technology. The system has the potential to solve many of the problems associated with the effective delivery of biologics, and we are very pleased to be continuing our collaboration with Monosol Rx.”
Mark Schobel, President and CEO of MonoSol Rx added: “Midatech’s ability to develop nanomedicines makes it an ideal partner to ensure we are able to fully exploit our PharmFilm® technology. Our film technology delivering nanoparticles provides new ways for the effective delivery of drug treatments that are attractive to patients and caregivers alike. In the case of biologics, especially in chronic care situations, the ability to provide therapeutic value without regular injections can provide a vast improvement over current therapies.”
The Nanoparticle film delivery system could be used to overcome the difficulties associated with the delivery of biologic therapies to the circulatory system, allowing for an efficient delivery system of biologics, through buccal or sublingual administration.
The delivery system facilitates transport of a therapy into the bloodstream without exposure to the gastrointestinal tract of the patient, avoiding gastrointestinal destruction and/or side-effects often associated with the oral drug delivery of certain molecules. Additionally, the combination of these technologies allows for the oral delivery of an entire class of therapies previously available primarily through injection.
The joint patent application relates to film delivery systems comprising nanoparticles, particularly for use in medicine, and includes methods and systems for the treatment of disorders of blood glucose in diabetic conditions. The patent is directed at compositions, delivery systems, products and methods of making and administering such compositions to sufferers.
Commenting on the filing of the patent, Professor Tom Rademacher, Chairman of Midatech Group said: “The filing of this patent will enable us to fully commercialize this exciting new drug delivery technology. The system has the potential to solve many of the problems associated with the effective delivery of biologics, and we are very pleased to be continuing our collaboration with Monosol Rx.”
Mark Schobel, President and CEO of MonoSol Rx added: “Midatech’s ability to develop nanomedicines makes it an ideal partner to ensure we are able to fully exploit our PharmFilm® technology. Our film technology delivering nanoparticles provides new ways for the effective delivery of drug treatments that are attractive to patients and caregivers alike. In the case of biologics, especially in chronic care situations, the ability to provide therapeutic value without regular injections can provide a vast improvement over current therapies.”
